share_log

S-1: General form for registration of securities under the Securities Act of 1933

S-1: General form for registration of securities under the Securities Act of 1933

S-1:證券上市註冊聲明
美股SEC公告 ·  11/23 05:41

Moomoo AI 已提取核心訊息

Cardio Diagnostics Holdings, Inc., formed through a merger in October 2022, specializes in AI-driven DNA biomarker tests for cardiovascular diseases. Despite innovative products like Epi+Gen CHD™ and PrecisionCHD™, the company reported minimal revenue and a net loss of $8.4 million in 2023. As of September 30, 2024, it holds $3 million in cash.The company trades on Nasdaq under CDIO but received a notice of non-compliance with the $1 minimum bid price. Leadership includes CEO Meeshanthini Dogan and CFO Elisa Luqman. Cardio Diagnostics raised funds through various means, including a $5 million convertible debenture in March 2023 and a $1 million private placement in February 2024.Key risks involve limited operating history and the need for additional capital. The company focuses on commercializing its tests through telemedicine and healthcare providers.
Cardio Diagnostics Holdings, Inc., formed through a merger in October 2022, specializes in AI-driven DNA biomarker tests for cardiovascular diseases. Despite innovative products like Epi+Gen CHD™ and PrecisionCHD™, the company reported minimal revenue and a net loss of $8.4 million in 2023. As of September 30, 2024, it holds $3 million in cash.The company trades on Nasdaq under CDIO but received a notice of non-compliance with the $1 minimum bid price. Leadership includes CEO Meeshanthini Dogan and CFO Elisa Luqman. Cardio Diagnostics raised funds through various means, including a $5 million convertible debenture in March 2023 and a $1 million private placement in February 2024.Key risks involve limited operating history and the need for additional capital. The company focuses on commercializing its tests through telemedicine and healthcare providers.
成立於2022年10月的心血管診斷控股公司專注於人工智能驅動的DNA生物標誌物檢測心血管疾病。儘管擁有像Epi+Gen CHD™和PrecisionCHD™這樣的創新產品,但該公司在2023年報告了微薄的營業收入和840萬美元的淨虧損。截至2024年9月30日,該公司持有300萬美元現金。該公司在納斯達克交易,股票代碼爲CDIO,但收到了不符合1美元最低買盤價格的不合規通知。領導團隊包括首席執行官Meeshanthini Dogan和首席財務官Elisa Luqman。心血管診斷通過多種方式籌集資金,包括於2023年3月發行的500萬美元可轉換債券和於2024年2月進行的100萬美元定向增發。主要風險涉及有限的運營歷史和需要額外資本。該公司專注於通過遠程醫療和醫療服務提供商推廣其測試。
成立於2022年10月的心血管診斷控股公司專注於人工智能驅動的DNA生物標誌物檢測心血管疾病。儘管擁有像Epi+Gen CHD™和PrecisionCHD™這樣的創新產品,但該公司在2023年報告了微薄的營業收入和840萬美元的淨虧損。截至2024年9月30日,該公司持有300萬美元現金。該公司在納斯達克交易,股票代碼爲CDIO,但收到了不符合1美元最低買盤價格的不合規通知。領導團隊包括首席執行官Meeshanthini Dogan和首席財務官Elisa Luqman。心血管診斷通過多種方式籌集資金,包括於2023年3月發行的500萬美元可轉換債券和於2024年2月進行的100萬美元定向增發。主要風險涉及有限的運營歷史和需要額外資本。該公司專注於通過遠程醫療和醫療服務提供商推廣其測試。
声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息